R&D

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases
Brii BiosciencesHKG: 2137

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Brii Biosciences Limited (HKG: 2137) announced the launch of its proprietary BRiSC (Bispecific RNAi iSilenCing) small interfering RNA (siRNA) drug discovery platform, designed to advance the development of next‑generation ribonucleic…

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis

Insilico Medicine Nominates ISM9546 as Preclinical Candidate – Oral, Peripherally Restricted VAV1 Molecular Glue Degrader Targets IBD and Rheumatoid Arthritis

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal
AIHKG: 3696

Insilico Medicine Partners with Servier on $888 Million AI Oncology Deal

Bio-Sincerity UCAS R&D Center Pharma Synthesis
Bio-Sincerity Pharmaceutical TechnologySHE: 301096

Bio-Sincerity UCAS R&D Center Pharma Synthesis

Simcere Halts R&D on Alzheimer's Drug Candidates Amid Pipeline Setbacks
Clinical trial resultsHKG: 2096

Simcere Halts R&D on Alzheimer’s Drug Candidates Amid Pipeline Setbacks

Ascletis Pharma's ASC47 Outperforms Semaglutide in Weight Loss Study
Ascletis PharmaCombination therapy

Ascletis Pharma’s ASC47 Outperforms Semaglutide in Weight Loss Study

Show More